BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21268743)

  • 1. Erythropoietin in kidney disease and type 2 diabetes.
    Donnelly S
    N Engl J Med; 2011 Jan; 364(4):385; author reply 385-6. PubMed ID: 21268743
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin in kidney disease and type 2 diabetes.
    Schnuelle P; Benck U; Krämer BK
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietin in kidney disease and type 2 diabetes.
    Thum T; Kalantar-Zadeh K; Anker SD
    N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin in kidney disease and type 2 diabetes.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
    N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
    N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia: To TREAT or not to TREAT--that is the question.
    Wiecek A
    Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
    Hayes C; Alam A; Black-Peart J; McFarlane SI
    Curr Diab Rep; 2010 Apr; 10(2):87-9. PubMed ID: 20425565
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetes, anemia and CKD: Why TREAT?
    Singh AK
    Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 12. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
    Rao M; Pereira BJ
    Kidney Int Suppl; 2003 Nov; (87):S12-9. PubMed ID: 14531768
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of anemia in chronic kidney disease--strategies based on evidence.
    Marsden PA
    N Engl J Med; 2009 Nov; 361(21):2089-90. PubMed ID: 19880845
    [No Abstract]   [Full Text] [Related]  

  • 16. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
    Hudson JQ; Sameri RM
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis.
    Brown JN; Kemp DW; Brice KR
    Pharmacotherapy; 2009 Apr; 29(4):468-72. PubMed ID: 19323622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa for treatment of anaemia in a case of chronic renal failure during pregnancy--case report.
    Ghosh A; Ayers KJ
    Clin Exp Obstet Gynecol; 2007; 34(3):193-4. PubMed ID: 17937101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.